Risk of Alzheimer's disease–related medication prescriptions in patients with type 2 diabetes (comparison between matched semaglutide vs other anti–diabetes medications groups)

Size/Group	Exposure Group	Comparison Group	Exposure Group Cases (Overall Risk)	Comparison Group Cases(Overall Risk)		HR (95% CI)
17,087	Semaglutide	Insulin	136 (0.80%)	243 (1.42%)		0.50 (0.41–0.62)
17,080	Semaglutide	Metformin	135 (0.79%)	183 (1.07%)		0.71 (0.57–0.88)
15,878	Semaglutide	DPP–4i	131 (0.83%)	201 (1.27%)		0.61 (0.49–0.76)
15,288	Semaglutide	SGLT2i	129 (0.84%)	152 (0.99%)		0.79 (0.63–1.00)
16,503	Semaglutide	SU	135 (0.82%)	190 (1.15%)		0.66 (0.53–0.83)
10,847	Semaglutide	TZD	108 (1.00%)	169 (1.56%)		0.59 (0.46–0.75)
17,029	Semaglutide	Other GLP–1RAs	136 (0.80%)	177 (1.04%)		0.74 (0.59–0.93)

Hazard Ratio (HR)
0.10 0.20 0.40 0.70 2.0 3.00 5.00 8.00